Free Trial
NASDAQ:CRME

Cardiome Pharma (CRME) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.30
$2.45
50-Day Range
N/A
52-Week Range
$1.29
$4.84
Volume
90,444 shs
Average Volume
135,322 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CRME stock logo

About Cardiome Pharma Stock (NASDAQ:CRME)

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

CRME Stock News Headlines

Biden’s parting shot at AI could create the perfect buying opportunity
Last week, we saw the largest single drop in semiconductor stock prices since the COVID crisis. All dropped nearly 10% or more.
Biden’s parting shot at AI could create the perfect buying opportunity
Last week, we saw the largest single drop in semiconductor stock prices since the COVID crisis. All dropped nearly 10% or more.
Jenny Sundqvist new CEO of InDex Pharmaceuticals
See More Headlines
Receive CRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiome Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2018
Today
7/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRME
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. William L. Hunter (Age 55)
    Pres, CEO & Director
  • Ms. Sheila M. Grant MBA
    Chief Operating Officer
  • Mr. David D. McMasters (Age 59)
    Gen. Counsel
  • Mr. Hugues Sachot
    Chief Commercial Officer
  • Mr. Justin A. Renz (Age 46)
    Chief Financial Officer

CRME Stock Analysis - Frequently Asked Questions

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Corp (NASDAQ:CRME) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to analysts' expectations of $7.34 million.

What other stocks do shareholders of Cardiome Pharma own?
This page (NASDAQ:CRME) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners